Urovant Sciences

Improving quality of life through innovations in urology.

Vibegron

Our lead product candidate, vibegron, is an investigational oral, once-daily, small molecule beta-3 agonist, being developed for overactive bladder (OAB), OAB in men with benign prostatic hyperplasia (BPH) and pain associated with irritable bowel syndrome (IBS). 

LEARN MORE

women-sleeping

Latest News

The latest posts and articles

Urovant Sciences to Present at…

June 3, 2019 at 8:00 AM EDT PDF Version IRVINE, Calif. & BASEL, Switzerland–(BUSINESS WIRE)–Jun. 3, 2019– Urovant…
Read Latest Post

Urovant Sciences to Present at…

May 30, 2019 at 8:00 AM EDT PDF Version IRVINE, Calif. & BASEL, Switzerland–(BUSINESS WIRE)–May 30, 2019– Urovant…
Read Latest Post

Urovant Sciences Initiates Phase 3…

PDF Version IRVINE, Calif. & BASEL, Switzerland–(BUSINESS WIRE)–Mar. 27, 2019– Urovant Sciences (Nasdaq: UROV),a clinical-stage…
Read Latest Post
UrovantSciences_PMS_KO

info@urovant.com

Terms of Use  |  Privacy Policy

Copyright 2018 © All Rights Reserved